Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Conditions

Relapsed/Refractory Multiple Myeloma(MM)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Xi'an No.3 Hospital, Xi’an, Shanxi, China

Study leads

Xiequn Chen, M.D.
Principal Investigator
Xi'an No.3 Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma · Relapse Multiple Myeloma · Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Boston, United States · Boston, United States

DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

Multiple Myeloma · Refractory Multiple Myeloma · Relapse Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Boston, United States

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Non Hodgkin Lymphoma · Richter Transformation · Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Chicago, United States · Boston, United States

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Neoplasms, Plasma Cell · Neoplasms by Histologic Type · Neoplasms

Abroad (travel likely)RecruitingPHASE1

Atlanta, United States